Sacituzumab govitecan

製品コード：D4002         Batch: D400201

印刷

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38, showing anticancer activity. Sacituzumab govitecan has a molecular weight of 160KDa. This product is supplied as 10mg/ml PBS solution.

製品説明

CAS No. 1491917-83-9 (Sacituzumab govitecan)
DAR 7.6
ADC antiody Sacituzumab
ADC cytotoxin SN-38
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping Shipped under low temperature conditions
Purity 98.93%
Protein concentration 10mg/ml
Endotoxin Level ＜1EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy [ Cancer Discov, 2025, 10.1158/2159-8290.CD-24-1515] PubMed: 40762432
A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan [ Scientific Reports, 2025, 409] PubMed: nan
TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications [ J Oral Pathol Med, 2025, 10.1111/jop.70008] PubMed: 40624990
TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications [ Journal of Oral Pathology & Medicine, 2025, 658-666] PubMed: 40624990.0
TROP2 Expression and Therapeutic Implications in Cutaneous Squamous Cell Carcinoma: Insights From Immunohistochemical and Functional Analysis [ Experimental Dermatology, 2024, e15196] PubMed: 39422290.0

人間や獣医の診断であるか治療的な使用のためにでない。